


ASSISI (PG)
15/17
GIUGNO 2023
Grand Hotel Assisi

**Congresso
Nazionale
PIEDE DIABETICO
GDS AMD-SID**

La **S**indrome
del **pie**de **diab**etico:
competenze
in azione
con uno sguardo
al futuro



1222 • 2022
800
A N N I



UNIVERSITÀ
DEGLI STUDI
DI PADOVA


NOVITA' IN TEMA DI FISIOPATOLOGIA DELLA MALATTIA CARDIOVASCOLARE DEL DIABETE

Angelo Avogaro

In qualità di RELATORE, ai sensi dell'art.76 sul Conflitto di Interessi dell'Accordo Stato-Regioni del 2 febbraio 2017, dichiaro che negli ultimi due anni ho avuto i seguenti rapporti di finanziamento con soggetti portatori di interessi commerciali in campo sanitario:


AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly,
Mundipharma, Neopharmed, Amgen, Servier, Merck
Sharp & Dohme, Novo Nordisk, Sanofi, Takeda, Amarin

Modifiable CV risk factors are common in patients with T2D



1. Svensson et al. Diab Vasc Dis Res 2013;10:520–9. 2. Das et al. Am Heart J 2006;151:1087–93.

INTERHEART: Impact of multiple risk factors on CV risk. The 4 major Modifiable Risk Factor account for the 90% of AMI



Smk = smoking
DM = diabetes
HTN = hypertension
Obes = obesity
Ps = psychosocial factors


Note: odds ratio plotted on a doubling scale

Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Non-diabetic Adults


Elizabeth Selvin, Michael Steffes, Hong Zhu, Kunihiro Matusushita, et al.

Data from 11,092 black and white subjects in the ARIC trial (Atherosclerosis Risk in Communities)
Median follow approximately 14 years.

B




Renal disease is associated with increased all-cause mortality



*Includes participants with or without diabetes and chronic kidney disease.


Tonelli et al. Lancet 2012;380(9844):807–14.




Protective
Factors

Plaque formation/Progression


Risk
Factors




The origin of Resolvins




Resolution versus chronic inflammation in atherosclerosis.



Circulating HSPC during the natural history of type 2 diabetes




Circulating HSPC during the natural history of type 2 diabetes



Circulating stem cells and cardiovascular outcomes: from basic science to the clinic

Gian Paolo Fadini^{1*}, Anurag Mehta², Devinder Singh Dhindsa²,
Benedetta Maria Bonora¹, Gopalkrishna Sreejit³, Prabhakara Nagareddy³, and
Arshed Ali Quyyumi²




Clinical Track


Autologous Cell Therapy for Peripheral Arterial Disease Systematic Review and Meta-Analysis of Randomized, Nonrandomized, and Noncontrolled Studies

Mauro Rigato, Matteo Monami, Gian Paolo Fadini


Primary analysis: ABI




Primary analysis: TcO₂




Primary analysis: pain score




Primary analysis: Pain-free walking distance




Somatic Mutations in Cardiovascular Disease




Clonal hematopoiesis of indeterminate potential as a precursor state for hematological neoplasms






Gumuser ED, et al. J Am Coll Cardiol. 2023;81(20):1996-2009.

Clonal hematopoiesis and mechanisms that might accelerate atherothrombotic risk





Inflammasomes and Atherosclerosis



Gian Paolo Fadini,^{1,2} Lisa Menegazzo,^{1,2} Mauro Rigato,¹ Valentina Scattolini,^{1,2}
 Nicol Poncina,^{1,2} Andrea Bruttocao,¹ Stefano Cicilot,^{1,2} Fabio Mammano,^{2,3}
 Catalin Dacian Ciubotaru,⁴ Enrico Brocco,⁵ Maria Cristina Marescotti,¹
 Roberta Cappellari,¹ Giorgio Arrigoni,^{6,7} Renato Millionsi,^{1,7}
 Saula Vigili de Kreutzenberg,¹ Mattia Albiero,^{1,2} and Angelo Avogaro^{1,2}

NETosis Delays Diabetic Wound Healing in Mice and Humans




Diabetes 2016;65:1061–1071 | DOI: 10.2337/db15-0863






A miR-125/Sirtuin-7 pathway drives the pro-calcific potential of myeloid cells in diabetic vascular disease

Saula Vigili de Kreutzenberg¹ • Alessandra Giannella¹ • Giulio Ceolotto¹ • Elisabetta Faggin¹ • Roberta Cappellari^{1,2} • Marta Mazzucato¹ • Chiara Fraccaro³ • Giuseppe Tarantini³ • Angelo Avogaro¹ • Gian Paolo Fadini^{1,2}











A miR-125/Sirtuin-7 pathway drives the pro-calcific potential of myeloid cells in diabetic vascular disease

Saula Vigili de Kreutzenberg¹ • Alessandra Giannella¹ • Giulio Ceolotto¹ • Elisabetta Faggin¹ • Roberta Cappellari^{1,2} • Marta Mazzucato¹ • Chiara Fraccaro³ • Giuseppe Tarantini³ • Angelo Avogaro¹ • Gian Paolo Fadini^{1,2}





1222 • 2022
800
ANNI



UNIVERSITÀ
DEGLI STUDI
DI PADOVA

Ringraziamenti

**Gian Paolo, Saula, Giulio, Mattia, Alessandra,
Benedetta, Mario Luca, Roberta**